DCF Tool

SYK

Stryker Corp. – Surgical and Medical Instrument Manufacturing
Stryker is one of the world's leading medical technology companies and, together with its customers, is driven to make healthcare better. The company offers innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes.
Analysis Results
Intrinsic Value $1,487.51
Latest Price $202.54
Relative Value 86% undervalued
Thoughts on this result? Let us know.
Ad
Cash Flow (Billions)
Analysis Parameters
%
%
%
New Ticker
Ad
Analysis Details
Growth Rate Projection

An exponential growth model was fit to the past cash flow data, giving more weight to more recent years. This model determined a growth rate estimate of 35.9%.

Weighted Average Cost of Capital (WACC)

The calculated WACC is 6.8%. This value is used as the default discount rate.

Value of Future Flows

Assuming a growth rate of 35.9%, the cash flows for the next 5 years are projected.

The present value of each year's flow is adjusted to present value using the discount rate.

Year Future flow (billion) Present value (billion)
2022 9.98 9.34
2023 13.6 11.9
2024 18.4 15.1
2025 25.0 19.2
2026 34.0 24.4
Terminal Value

Assuming a growth rate after the projection years of 2.0%, the terminal value of the company would be 717 billion. This corresponds to a present value of 483 billion.

Intrinsic Value Per Share

The total present value of the projected cash flows is 80.0 billion. Adding in the terminal value gives a total present value of 563 billion.

There are presently 378.0 million outstanding shares, so the intrinsic value per share is 1487.51.

Financial Statements

The following data was to determine the past cash flows.

Current Assets 20,034,000,000
Current Cash 6,038,000,000
Current Liabilities 9,098,000,000
Current Debt 14,000,000
Non-Cash Working Capital (NCWC) 4,912,000,000
Change in NCWC 2,509,000,000
EBIT 5,168,000,000
Tax Provision 574,000,000
Depreciation and Amortization 1,980,000,000
Capital Expenditure -1,050,000,000
Unlevered Free Cash Flow 7,956,751,863
Current Assets 9,707,000,000
Current Cash 3,024,000,000
Current Liabilities 5,041,000,000
Current Debt 761,000,000
Non-Cash Working Capital (NCWC) 2,403,000,000
Change in NCWC -991,000,000
EBIT 2,223,000,000
Tax Provision 355,000,000
Depreciation and Amortization 812,000,000
Capital Expenditure -487,000,000
Unlevered Free Cash Flow 1,153,128,454
Current Assets 11,360,000,000
Current Cash 4,425,000,000
Current Liabilities 4,400,000,000
Current Debt 859,000,000
Non-Cash Working Capital (NCWC) 3,394,000,000
Change in NCWC 794,000,000
EBIT 2,713,000,000
Tax Provision 479,000,000
Depreciation and Amortization 778,000,000
Capital Expenditure -649,000,000
Unlevered Free Cash Flow 3,128,768,540
Current Assets 9,733,000,000
Current Cash 3,699,000,000
Current Liabilities 4,807,000,000
Current Debt 1,373,000,000
Non-Cash Working Capital (NCWC) 2,600,000,000
Change in NCWC 253,000,000
EBIT 2,537,000,000
Tax Provision -1,197,000,000
Depreciation and Amortization 723,000,000
Capital Expenditure -572,000,000
Unlevered Free Cash Flow 2,941,000,000
Current Assets 7,993,000,000
Current Cash 2,793,000,000
Current Liabilities 3,485,000,000
Current Debt 632,000,000
Non-Cash Working Capital (NCWC) 2,347,000,000
Change in NCWC 790,000,000
EBIT 2,290,000,000
Tax Provision 1,043,000,000
Depreciation and Amortization 642,000,000
Capital Expenditure -598,000,000
Unlevered Free Cash Flow 1,966,234,609
Current Assets 7,861,000,000
Current Cash 3,384,000,000
Current Liabilities 3,148,000,000
Current Debt 228,000,000
Non-Cash Working Capital (NCWC) 1,557,000,000
Change in NCWC 426,000,000
EBIT 2,166,000,000
Tax Provision 274,000,000
Depreciation and Amortization 546,000,000
Capital Expenditure -490,000,000
Unlevered Free Cash Flow 2,339,054,659
Current Assets 7,944,000,000
Current Cash 4,079,000,000
Current Liabilities 3,503,000,000
Current Debt 769,000,000
Non-Cash Working Capital (NCWC) 1,131,000,000
Change in NCWC 195,000,000
EBIT 1,861,000,000
Tax Provision 296,000,000
Depreciation and Amortization 397,000,000
Capital Expenditure -270,000,000
Unlevered Free Cash Flow 1,865,503,746
Current Assets 9,673,000,000
Current Cash 5,000,000,000
Current Liabilities 4,464,000,000
Current Debt 727,000,000
Non-Cash Working Capital (NCWC) 936,000,000
Change in NCWC -787,000,000
EBIT 1,246,000,000
Tax Provision 645,000,000
Depreciation and Amortization 378,000,000
Capital Expenditure -233,000,000
Unlevered Free Cash Flow -88,818,965
Current Assets 8,335,000,000
Current Cash 3,980,000,000
Current Liabilities 2,657,000,000
Current Debt 25,000,000
Non-Cash Working Capital (NCWC) 1,723,000,000
Change in NCWC -280,000,000
EBIT 1,304,000,000
Tax Provision 206,000,000
Depreciation and Amortization 307,000,000
Capital Expenditure -195,000,000
Unlevered Free Cash Flow 914,363,036
Current Assets 8,148,000,000
Current Cash 4,285,000,000
Current Liabilities 1,876,000,000
Current Debt 16,000,000
Non-Cash Working Capital (NCWC) 2,003,000,000
Change in NCWC 21,000,000
EBIT 1,816,000,000
Tax Provision 407,000,000
Depreciation and Amortization 277,000,000
Capital Expenditure -210,000,000
Unlevered Free Cash Flow 1,470,503,225

This analysis is provided for informational purposes only and does not constitute financial or investing advice. For more information on the advantages and limitations of DCF analysis see background. This information is provided on an "as is" basis. No warranty, expressed or implied, is made regarding accuracy, adequacy, completeness, legality, reliability or usefulness of any information. By using this site you agree that under no circumstances shall Valuation Tools LLC be held liable for any loss or damage caused by information obtained from this website including any articles, data, videos, its social media accounts, or any other materials.